Lithium: Toxic Placebo or Magic Ion?
Free Public Lecture
Ian Potter Auditorium
Kenneth Myer Building
Royal Parade, Parkville
T: 8344 5509
Lithium was reintroduced to medicine following John Cade’s seminal paper in 1949 and the pioneering work of Mogens Schou. Lithium faced early scepticism from the Maudsley Hospital and these views persisted until quite recently. Lithium is now universally agreed to have robust evidence underpinning its clinical use in mood disorders, both bipolar and unipolar. Lithium treatment is also associated with a reduced rate of death by suicide in mood disorder.
Intriguing literature has emerged in recent years suggesting positive health benefits from increased levels of lithium in the drinking water. Although these are trace level compared to therapeutic doses they do seem to impact health.
A major challenge is to identify which patients will benefit from lithium. The lecture will end with a discussion of approaches to evaluating biomarkers of lithium response.
Professor Allan Young is the Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King’s College, London.
Professor Allan Young, Chair of Mood Disorders, Director of the Centre for Affective Disorders in the Department of Psychological Medicine
Professor Allan Young
Chair of Mood Disorders, Director of the Centre for Affective Disorders in the Department of Psychological Medicine
Institute of Psychiatry at King’s College London
Professor Allan Young holds the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King’s College London, UK. Professor Young is the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) Theme lead in the Translational Therapeutics Cluster. Professor Young is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust where he is also a Consultant Psychiatrist and the head of the National Affective Disorders Tertiary Clinic. Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. Professor Young is a member of a number of editorial boards and of numerous professional and scientific societies. He is currently President of the International Society for Affective Disorders and President Elect of the British Association of Psychopharmacology